On October 10, 2025, Lam Dong Pharmaceutical Joint Stock Company (Ladophar, stock code: LDP) announced that it had received the Judgment dated September 23 from the People’s Court of Zone I – Lam Dong regarding the dispute over disciplinary actions, termination, and unilateral termination of the labor contract between the Plaintiff, Ms. Le Thi Minh Thuy (born in 1985), and the Defendant, Lam Dong Pharmaceutical Joint Stock Company (Ladophar).
Ms. Le Thi Minh Thuy (left).
Case Details as per Ms. Le Thi Minh Thuy’s Lawsuit
Ms. Le Thi Minh Thuy was an employee at Ladophar under an indefinite-term labor contract signed on December 1, 2022. At the time of employment, she held the position of CEO.
On December 20, 2023, Ladophar held an Extraordinary Shareholders’ Meeting, during which Ms. Thuy’s position as CEO was revoked. Disagreeing with this decision, Ms. Thuy requested Ladophar to provide details on the procedures and reasons for her dismissal. However, Ladophar did not respond to her request.
Subsequently, on June 12, 2024, Ladophar issued a “Disciplinary Action Decision” and a “Notice of Disciplinary Action” to terminate Ms. Thuy’s employment.
Ms. Thuy argued that this decision was unjustified for the following reasons:
First, Ladophar held an Extraordinary Shareholders’ Meeting and revoked her position as CEO without providing any explanation. Ms. Thuy stated that throughout her tenure, she had always fulfilled her responsibilities and successfully completed her assigned tasks.
Second, Ladophar signed an indefinite-term labor contract with Ms. Thuy. Therefore, revoking her position as CEO did not automatically terminate her employment relationship with the company. Additionally, after her dismissal, the company did not assign her to another suitable position.
Furthermore, Ladophar’s claim that Ms. Thuy had not reported to work since December 21, 2023, was inaccurate. On December 20, 2023, during the Extraordinary Shareholders’ Meeting, after announcing her dismissal, the company instructed security personnel to lock her office, preventing her from retrieving her personal belongings, which made it impossible for her to return to work.
Ms. Thuy was a dedicated and responsible employee who contributed significantly to the company’s growth. Throughout her employment, there were no disagreements between her and Ladophar.
Ms. Thuy requested the court to:
– Declare Ladophar’s decision to revoke her position as CEO unlawful;
– Annul the “Disciplinary Action Decision” and order Ladophar to pay her salary and social insurance contributions from December 2023 until the case is resolved. The total amount claimed is nearly 2 billion VND.
Ladophar’s Statement
During her tenure, Ms. Thuy failed to perform her duties effectively, leading to significant operational losses in 2023, which adversely affected the shareholders’ interests, the company’s survival, and the employment and income of all employees.
Additionally, while receiving a high salary, Ms. Thuy exploited her position for personal gain by creating expenses through vehicle rental contracts with her relatives, thereby siphoning company funds for personal benefit.
Unable to tolerate her misconduct, Ladophar convened an Extraordinary Shareholders’ Meeting in 2023 to revoke her position as CEO.
Following her dismissal, Ms. Thuy engaged in unlawful activities, including misappropriating the company’s seal, refusing to report to work, and continuously harassing the company for benefits, despite no formal termination decision having been made.
The company repeatedly invited Ms. Thuy to discuss work handover and return the seal, but she refused, aiming to pressure the management and disrupt internal operations. The company documented these actions through notarized records, leading to her termination.
Lam Dong Pharmaceutical Joint Stock Company requested the court to reject Ms. Thuy’s claims and compensation demands.
Court Decision
After reviewing the case files and deliberations in court, the Judicial Council found no legal basis for the plaintiff’s claims.
The court ruled not to accept Ms. Le Thi Minh Thuy’s lawsuit regarding the “Dispute over disciplinary actions, termination, and unilateral termination of the labor contract” against Lam Dong Pharmaceutical Joint Stock Company (Ladophar).
Regarding court fees, Ms. Le Thi Minh Thuy is exempt from advance payment.
Removing All Party Positions Held by Mr. Do Trong Hung
On the morning of October 6th, the 13th Plenary Session of the Central Committee of the Communist Party of Vietnam, 13th tenure, convened in Hanoi. During the session, the Central Committee deliberated and decided to impose disciplinary action on Mr. Đỗ Trọng Hưng, removing him from all Party positions.
Shocking Twist in ‘Mistaken Construction’ on Red Book Land: Landowner Reveals Startling Details
A landowner in Thien Huong Ward, Hai Phong City, claims their plot was unlawfully seized by strangers who brazenly constructed a house on it. The owner suspects the trespassers intentionally claimed a “mistaken build” to circumvent the property’s proximity to a grave, a factor that could devalue the land.
The Company’s Move: A Tale of Market Manipulation by its Former Leadership
“Lam Dong Pharmaceutical Joint Stock Company is set to offer almost 14 million shares to three investors, including the Dynamic Vision Investment Fund, HD Fund Management Joint Stock Company, and APC Holdings Joint Stock Company, to raise VND 150 billion. This company was once led by Mr. Do Thanh Nhan, who was arrested for ‘Manipulating the securities market’.”
The Chairman of Ladophar’s Board of Directors Seeks to Divest Majority of Shareholdings
Mr. Pham Trung Kien, Chairman of the Board of Directors at Ladophar, has announced his intention to sell over 1.08 million LDP shares to reduce his ownership to 88,792 shares, equivalent to 0.7% of the company’s charter capital.
The Chairman of Ladophar seeks to offload a significant portion of his holdings as the company’s shares soar to new heights.
Mr. Pham Trung Kien, Chairman of the Board of Directors of Ladophar, a leading pharmaceutical company in Vietnam, has recently filed to sell over 1.08 million shares of the company’s stock, equivalent to 8.1% of its capital. If the transaction is successful, Mr. Kien’s ownership will decrease to 0.7%, and he will no longer be a major shareholder. The sale is intended for portfolio restructuring and will be executed through matched orders and/or put-through transactions between August 29 and September 27.
